Abstract: A substrate for a dual interface smartcard, comprising a contact pad module receiving portion; an auxiliary module receiving portion; and a conductor pattern. The conductor pattern includes an antenna coil having a first end and a second end; a first set of connectors arranged in the contact pad module and including a GND connector and a VCC connector for electrical connection with a VCC connector of the contact pad module; a second set of connectors arranged in the auxiliary module receiving portion and including a GND connector and a VCC connector; and leads connecting connectors in the first set with connectors in the second set. One of the GND connector and the VCC connector in the first set of connectors is conductively connected to one of the first end and the second end of the antenna coil.

Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

Abstract: A pharmaceutical formulation comprising an erosion matrix comprising one or more fumaric acid esters as well as one or more rate-controlling agents, wherein erosion of said erosion matrix permits controlled release of said fumaric acid ester(s).

Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

Abstract: A pharmaceutical formulation comprising an erosion matrix comprising one or more fumaric acid esters as well as one or more rate-controlling agents, wherein erosion of said erosion matrix permits controlled release of said fumaric acid ester(s).

Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and arc designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

Abstract: Embodiments of the invention provide a zipper attached safety layer applied between a flexible mat and an edge pad of a trampoline. The safety layer moves with the flexible mat and prevents a user from accidently inserting an appendage into the suspension system (e.g., coiled springs) of the trampoline. Embodiments of the invention further relate to a trampoline comprising such a zippered safety layer and to a method of arranging the safety layer in a trampoline.

Abstract: A vehicle driveline system for a vehicle is provided. The system comprises a differential (110) having two output shafts (111,112) being connectable with respective wheel shafts, a primary electrical motor (121) being connected with a driving input (117) of the differential (110) via a first reduction gearing (130), said first reduction gearing (130) being connected to a secondary electrical motor (122) for adjusting the gear ratio of the first reduction gearing (130); whereby the secondary electrical motor (122) is connected to a clutch arrangement (150) configured to selectively lock the gear ratio of the first reduction gearing (130).

Abstract: A hydraulic system (10) for a vehicle is provided. The hydraulic system comprises a shifting mechanism (20) and a pump assembly (30) configured to provide pressurized fluid to said shifting mechanism (20), and an electrical motor (40). The movement of the shifting mechanism (20) controls a valve function which serves to open a connection from the pump assembly (30) to the electrical motor (40).

Abstract: Embodiments of the invention provide a zipper attached safety layer applied between a flexible mat and an edge pad of a trampoline. The safety layer moves with the flexible mat and prevents a user from accidently inserting an appendage into the suspension system (e.g., coiled springs) of the trampoline. Embodiments of the invention further relate to a trampoline comprising such a zippered safety layer and to a method of arranging the safety layer in a trampoline.

Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

Abstract: A pharmaceutical formulation comprising an erosion matrix comprising one or more fumaric acid esters as well as one or more rate-controlling agents, wherein erosion of said erosion matrix permits controlled release of said fumaric acid ester(s).

Abstract: A method is provided for controlling the injection, by a reductant injector in an exhaust system for an internal combustion engine, of reductant for an exhaust aftertreatment unit of the exhaust system, for example a selective catalytic reduction (SCR) unit. The method includes determining a reductant injection debt in dependence on a reductant flow according to at least a first request being higher than a threshold of the reductant flow, and, at least partly in dependence on the reductant injection debt, controlling the reductant injector so as to inject a compensation flow.

Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

Abstract: A final drive for a road vehicle comprises a pinion gear on a pinion axle journaled in a housing, the pinion gear being in gear engagement with a crown gear journaled for rotation transversely to the pinion axle. The final drive is combined with an all wheel drive (AWD) coupling, comprising a disc package axially controlled by a hydraulic piston for optionally transmitting torque from an ingoing axle to the pinion axle, the disc package being rotatably connected to the pinion axle. The ingoing axle of the AWD coupling is radially journaled only by the pinion axle in the final drive.

Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.